Literature DB >> 2229382

Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera.

M Verdier1, F Denis, G Leonard, A Sangare, S Patillaud, M Prince-David, M Essex.   

Abstract

The effectiveness of four screening tests for detecting antibody to human T-cell leukemia virus type I (HTLV-I) was determined by using 2,700 African serum specimens. The tests studied were indirect immunofluorescence, particle agglutination from Fujirebio, and two enzyme immunoassays, one from Abbott Laboratories that used virus lysate from HUT 102 cells and the other from Cambridge BioScience Corp. that used an env recombinant protein. Positive and doubtful sera were confirmed by Western immunoblot and radioimmunoprecipitation assay with Food and Drug Administration seropositivity criteria. The best results were obtained with the two enzyme immunoassays, which were more sensitive (100 and 98.6% [Abbott and Cambridge, respectively]) and more specific (98.7 and 96.5%). Indirect immunofluorescence exhibited difficulties for reading and interpretation. With particle agglutination, prozone was observed for 9 of 78 HTLV-I-positive serum specimens. False-positives in any of the tests were not linked to cross-reactions with human immunodeficiency viruses. However, confirmation tests remain necessary for HTLV-I screening.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229382      PMCID: PMC268091          DOI: 10.1128/jcm.28.9.1988-1993.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

2.  Comparative diagnostic assay results for detecting antibody to HTLV-I in Japanese blood donor samples: higher positivity rates by particle agglutination assay [corrected].

Authors:  J Ishizaki; A Okayama; N Tachibana; T Yokota; E Shishime; K Tsuda; N Mueller
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

3.  Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people.

Authors:  Y M Chen; T H Lee; K P Samuel; A Okayama; N Tachibana; I Miyoshi; T S Papas; M Essex
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I.

Authors:  D Gallo; M N Hoffman; C K Cossen; J L Diggs; J W Hurst; L M Penning
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

5.  Prevalence of antibody to human T cell leukemia virus type 1 (HTLV-1) in populations of Ivory Coast, West Africa.

Authors:  M Verdier; F Denis; A Sangaré; F Barin; G Gershy-Damet; J L Rey; B Soro; G Léonard; M Mounier; J Hugon
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

6.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Retrovirus-associated myelopathies.

Authors:  G C Román
Journal:  Arch Neurol       Date:  1987-06

8.  A new agglutination test for serum antibodies to adult T-cell leukemia virus.

Authors:  M Ikeda; R Fujino; T Matsui; T Yoshida; H Komoda; J Imai
Journal:  Gan       Date:  1984-10

9.  Comparative studies of commercially available particle agglutination assay and enzyme-linked immunosorbent assay for screening of human T-cell leukemia virus type I antibodies in blood donors.

Authors:  S Kobayashi; T Yoshida; Y Hiroshige; T Matsui; N Yamamoto
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Performance certification of gelatin particle agglutination assay for anti-HTLV-1 antibody: inconclusive positive results.

Authors:  Y Maeda; J Imai; H Kiyokawa; M Kanamura; S Hino
Journal:  Jpn J Cancer Res       Date:  1989-10
View more
  5 in total

1.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

2.  Use of dried blood spots for the detection and confirmation of HTLV-I specific antibodies for epidemiological purposes.

Authors:  S P Parker; M B Taylor; A E Ades; W D Cubitt; C Peckham
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

3.  Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel.

Authors:  C Fujiyama; T Fujiyoshi; D Matsumoto; H Tamashiro; S Sonoda
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

Review 4.  A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm.

Authors:  Rachael S Barr; Simon B Drysdale; Mary Boullier; Hermione Lyall; Lucy Cook; Graham P Collins; Dominic F Kelly; Lorna Phelan; Graham P Taylor
Journal:  Front Med (Lausanne)       Date:  2022-07-08

5.  Improvement of gelatin particle agglutination test for detection of anti-HTLV-I antibody.

Authors:  R Fujino; K Kawato; M Ikeda; H Miyakoshi; M Mizukoshi; J Imai
Journal:  Jpn J Cancer Res       Date:  1991-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.